...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Virology >JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France.
【24h】

JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France.

机译：肾移植患者外周血中的JC病毒DNA：在法国进行的1年前瞻性随访。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is little information on JC virus (JCV) infection in renal transplant patients. A long-term prospective follow-up study was conducted to assess the incidence of JCV DNA in the blood of 103 adult renal transplant patients enrolled prospectively between 1 January and 31 December 2006. Patients were monitored until April 2008. JCV DNA was quantified by a real-time polymerase chain reaction in whole blood samples collected regularly for at least 1 year post-transplant. JCV was detected in seven patients (6.8%) (31/1,487 whole blood samples) at a median time of 139 days post-transplant. The median JC virus load of the first positive DNA blood sample was 3.4 log(10) copies/ml (1.9-5.7 log(10) copies/ml). Induction therapy were either anti-CD25 monoclonal antibodies (n = 5) or antithymocyte globulins (n = 2). Post-transplant immunosuppressive treatment included steroids with tacrolimus/mycophenolate mofetil (MMF) (n = 2), or ciclosporin/MMF (n = 1), or belatacept/MMF (n = 4). Two patients were also treated with rituximab. All seven patients infected with JCV had other viral infections(s): BK virus (3), Epstein-Barr virus (2), Cytomegalovirus (1) or both BK virus and Epstein-Barr virus (1). Three patients had BKV-associated nephropathy and decoy cells shedding. JCV infection was not associated with acute rejection episodes or nephropathy, regardless of the virus load. No patient developed progressive multifocal leukoencephalopathy during follow-up. Thus the incidence of JCV infection in renal transplant patients was low and not associated with any specific clinical manifestations. JCV replication must still be diagnosed and differentiated from BK virus infection because of its non-aggressive course.
机译：肾移植患者中有关JC病毒（JCV）感染的信息很少。进行了一项长期的前瞻性随访研究，以评估2006年1月1日至12月31日期间前瞻性入组的103名成年肾移植患者血液中JCV DNA的发生率。监测患者直至2008年4月。至少在移植后1年内定期采集全血样品中的实时聚合酶链反应。在移植后139天的中位时间，在7名患者（6.8％）（31 / 1,487全血样本）中检测到JCV。第一个阳性DNA血液样本的JC病毒中位数为3.4 log（10）拷贝/ ml（1.9-5.7 log（10）拷贝/ ml）。诱导疗法是抗CD25单克隆抗体（n = 5）或抗胸腺细胞球蛋白（n = 2）。移植后免疫抑制治疗包括使用他克莫司/霉酚酸酯（MMF）（n = 2）或环孢素/ MMF（n = 1）或belatacept / MMF（n = 4）的类固醇。两名患者也接受利妥昔单抗治疗。感染JCV的所有7名患者均患有其他病毒感染：BK病毒（3），爱泼斯坦-巴尔病毒（2），巨细胞病毒（1）或BK病毒和爱泼斯坦-巴尔病毒（1）。三例患者患有BKV相关性肾病，诱饵细胞脱落。不论病毒载量如何，JCV感染均与急性排斥反应或肾病无关。随访期间无患者进展性多灶性白质脑病。因此，肾移植患者中JCV感染的发生率较低，并且与任何特定的临床表现无关。由于JCV复制过程不具侵略性，因此仍必须对其进行诊断并与BK病毒感染区分开。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号